TON - October 2012 Vol 5 No 9 published on November 19, 2012 in Cancer Center Profile
Fox Chase Cancer Center (FCCC) is 1 of 41 National Cancer In­stitute (NCI)-designated Comprehensive Cancer Centers (ie, “cen­ters of excellence” in the United States. FCCC was one of the first institutions to be awarded the elite NCI designation, which it received in 1974. In July 2012, FCCC joined the Temple Health System.
TON - October 2012 Vol 5 No 9 published on November 19, 2012
Although mammographic density is associated with increased risk of developing breast cancer, a new National Cancer Institute–sponsored study suggests that dense breasts do not increase the risk of death in women who are already diagnosed with breast cancer...
TON - October 2012 Vol 5 No 9 published on November 19, 2012 in Genetic Counseling
As with most cancers, the genetic contribution to breast cancer is often classified as sporadic, familial, and hereditary. The majority of breast cancer cases, approximately 70%, are considered sporadic; these cases do not run in families and are not believed to have an underlying genetic predisposition.
TON - October 2012 Vol 5 No 9 published on November 19, 2012 in Breast Cancer
Updated results from the pivotal phase 3 BOLERO-2 trial uphold, and even add to, the previous benefits reported for the addition of everolimus to exemestane in advanced breast cancer, including a positive effect on bone markers.
TON - October 2012 Vol 5 No 9 published on November 19, 2012 in FDA News & Updates
October is National Breast Cancer Awareness Month. The October 1, 2012, presidential proclamation acknowledging this points out that “Breast cancer touches the lives of Americans from every background and in every community across our Nation.”
TON - October 2012 Vol 5 No 9 published on November 19, 2012 in FDA News & Updates
The US Food and Drug Administration (FDA) approved regorafenib (Stivarga, Bayer HealthCare Pharmaceuticals, Inc.) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemo­therapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib approval was granted on September 27, 2012.
TON - October 2012 Vol 5 No 9 published on November 19, 2012
The incidence of heart failure and cardiomyopathy were significantly in­creased in women with breast cancer treated with trastuzumab either alone or in combination with anthracycline-based chemotherapy, according to the results of a recent large, population-based, retrospective cohort study...
TON - October 2012 Vol 5 No 9 published on November 19, 2012 in Noteworthy Numbers
Nearly 1 in 3 cancers diagnosed in women in the United States is breast cancer.
TON - October 2012 Vol 5 No 9 published on November 19, 2012
Ovarian cancer accounts for about 3% of all cancers in women. It is difficult to detect at early stages, so most women who present with the disease are at relatively advanced stages, when it is often fatal.
TON - October 2012 Vol 5 No 9 published on November 19, 2012 in The Patient's Voice
John Donne, a 16th century poet, wrote a work called “Death, be not proud” (also known as “Holy Sonnet 10”) about death. One line in particular always catches my attention: “….And soonest our best men with thee do go.” Donne stated the obvious: everyone dies, and for many, death comes too soon.
Page 1 of 2
Results 1 - 10 of 15